Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6635763 | 0.91 | DHFR (0.58) | ADORA2AADRA2AADRA2BADRA2C | |
| SCHEMBL6632402 | 0.90 | ADORA2A (0.63) | ADORA2AADRA2AADRA2BADRA2CADORA1 | |
| SCHEMBL6622066 | 0.89 | ADORA2A (0.61) | ADORA2AADRA2AADRA2BADRA2CADORA1 | |
| SCHEMBL6633156 | 0.88 | ADORA2A (0.63) | ADORA2AADRA2AADRA2BADRA2CADORA1 | |
| SCHEMBL6633371 | 0.86 | ADORA2A (0.65) | ADORA2AADRA2AADRA2BADRA2CADORA1 | |
| SCHEMBL6632376 | 0.85 | ADRA2A (0.53) | ADORA2AADRA2AADRA2BADRA2CADORA1 | |
| SCHEMBL6631798 | 0.83 | ADRA2A (0.59) | ADORA2AADRA2AADRA2BADRA2CADORA1 | |
| SCHEMBL6624412 | 0.83 | ADRA2A (0.62) | ADORA2AADRA2AADRA2BADRA2CADORA1 | |
| SCHEMBL6634127 | 0.82 | ADORA2A (0.65) | ADORA2AADRA2AADRA2BADRA2CADORA1 | |
| SCHEMBL6623375 | 0.82 | ADRA2A (0.67) | ADORA2AADRA2AADRA2BADRA2CADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | ADORA2A 89/4885ADRA2A 7/4885ADRA2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.